Daniel Lovell, MD, Pediatric Rheumatology, Cincinnati, OH

DanielJLovellMD

Pediatric Rheumatology Cincinnati, OH

Professor, Pediatrics, University of Cincinnati College of Medicine

Dr. Lovell is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lovell's full profile

Already have an account?

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Rheumatology, 1982 - 1984
  • University of Texas School of Public HealthM.P.H., Biostatistics/Study Design, 1982 - 1984
  • Children's Mercy HospitalResidency, Pediatrics, 1978 - 1981
  • University of Kansas School of Medicine
    University of Kansas School of MedicineClass of 1978
  • University of Kansas
    University of KansasB.A., Philosophy, 1969 - 1975

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2015 - 2017
  • OH State Medical License
    OH State Medical License 1984 - 2022
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Rheumatology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Innovative Educator Award American College of Rheumatology, 2007
  • Distinguished Clinical Investigator American College of Rheumatology, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016  
    Hermine I Brunner, Melissa L Mannion, Judyann C Olson, Vibeke Strand, Daniel J Lovell, Meredith P Riebschleger, Susan Shenoi, Journal of Rheumatology
  • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial  
    Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rocket..., Arthritis Rheum, 2/1/2013
  • American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis  
    Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric ..., Arthritis Care Res, 7/1/2011
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of double-blind withdrawal phase
    Block AJ, Ruperto N, Lovell DJ, Giannini EH, Martini A, Rheumatology, 1/1/2007
  • The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis
    Giannini EH, Ilowite NT, Lovell DJ, et al, Annals of Rheumatic Diseases, 1/1/2007
  • Safety of over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
    Lovell DJ, Giannini EH, Wallace CA et al, Annals of Rheumatic Diseases, 1/1/2007
  • Join now to see all

Other

  • What are growing pains, anyway? 
    Lovell DJ, McCall's
    5/1/1996

Press Mentions

  • The Greatest Rheumatologist - Part I
    The Greatest Rheumatologist - Part IOctober 25th, 2017
  • Lupus in Kids: Damage Starts Early
    Lupus in Kids: Damage Starts EarlyFebruary 5th, 2017
  • Questions and Answers About Juvenile Arthritis
    Questions and Answers About Juvenile ArthritisJune 13th, 2015
  • Join now to see all

Professional Memberships